Liquidia Stock Declines Following Adverse Patent Ruling in United Therapeutics Dispute

Key Facts

1Liquidia Corp shares continued their decline following a US federal court ruling that it infringed on United Therapeutics' patents.

Liquidia Corp shares continued their decline following a US federal court ruling that the company infringed on patents held by United Therapeutics. Benzinga reported that the legal defeat in this patent dispute has triggered an extended sell-off, impacting Liquidia's market position.

LQDA closed at $30.26 on September 30, 2026, after hitting a session low of $29.86. Meanwhile, United Therapeutics (UTHR) shares closed at $541.89 on September 30, 2026. Adverse rulings in the biotech sector are often linked to significant price corrections due to the potential loss of market exclusivity or delays in product launches.